Darunavir/Ritonavir (DRV/r)

DRUG3 trials

Sponsors

Janssen-Cilag G.m.b.H, Janssen-Cilag S.p.A., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsHuman Immunodeficiency Virus (HIV)Human Immunodeficiency Virus; HIVTuberculosis

Phase 3

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

CompletedNCT01516970

Janssen-Cilag G.m.b.HHuman Immunodeficiency Virus (HIV)

Start: 2011-11-25End: 2013-09-28Updated: 2017-07-19

Unknown Phase

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

CompletedNCT01541085

Janssen-Cilag S.p.A.Human Immunodeficiency Virus; HIV

Start: 2011-12-31End: 2013-06-30Updated: 2013-11-26

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

CompletedNCT04518228

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis

Start: 2021-09-01End: 2025-07-10Updated: 2025-11-12